Medicare Prescription BenefitInformation & Resources Medicare Prescription Benefit |
|
| Prescription| Prescription Resources | Prescription Marketing | |||
Prescription Drug Benefit Cost Understated by $324 Billion! By: Ian Mason: When the legislation was passed for Bush’s prescription drug benefit in 2003, costs were said to be approximately $400... I see. About the Author Ian Mason of Shoppe.MD Online Pharmacy ... Seniors at a Disadvantage When Purchasing Prescription Drugs Online By: Stephen Dayton: A recent national survey done by the Kaiser Family Foundation in association with Princeton Survey Research Associates... is something they “wouldn’t want to do without”, and more than half feel the Internet keeps them in touch with loved on... Prescription Eyeglasses Or Contact Lenses Which is Better ? By: Martin Smith: Many means have been used over time to correct vision. The monocle and eyeglass on a stick came before prescription e... get disposable contact lenses from online and from traditional eye care/wear places.You need a prescription for contact... Prescription Eyeglasses By: Timothy Gorman: In today's society, not only are prescription eyeglasses a necessity, but to some people they are a fashion accessory.... out the blue lights.* Yellow is especially helpful in dimmer conditions. * Rose is obviously pink in color and not high... Prescription eyeglass specialty lenses By: Timothy Gorman: There are many different lenses that have been specially created for certain purposes and needs. An aspheric lens is o... are also many different coatings that can be applied to your prescription eyeglasses. It can be done by the lens manufa... Press Release In the interests of cancer patients and oncologists nationwide, the Lorenzen Cancer Foundation (LCF), a non-profit dedicated to fighting pancreatic cancer, has joined the public interest law firm Washington Legal Foundation (WLF) and others today in presenting a written comments statement to the U.S. Centers for Medicare and Medicaid Services (CMS) voicing support for the Section 641 demonstration project and expressing concerns regarding CMS’s proposed restrictions limiting coverage of the drug benefit to exclude off-label uses of FDA-approved drug or biological therapies. Monterey, CA July 7, 2004 -- In the interests of cancer patients and oncologists nationwide, the Lorenzen Cancer Foundation (LCF), a non-profit dedicated to fighting pancreatic cancer, has joined the public interest law firm Washington Legal Foundation (WLF) and others today in presenting a written comments statement to the U.S. Centers for Medicare and Medicaid Services (CMS) voicing support for the Section 641 demonstration project and expressing concerns regarding CMS’s proposed restrictions limiting coverage of the drug benefit to exclude off-label uses of FDA-approved drug or biological therapies. Once the Food and Drug Administration approves a drug for marketing, physicians may prescribe the drug for purposes other than those that the FDA has given specific indication. Off-label prescribing is common in cancer treatment as drugs often work well for many types of cancer. A General Accounting Office analysis in 1991 demonstrated that over half of cancer patients received at least one off-label medicine in the course of their care. In enacting Section 641 of the Medicare Prescription Drug and Modernization Act of 2003, Congress did not exclude off-label uses from the demonstration project related to Section 641. To the contrary, Section 641(a) directs that the project be conducted following the standards of the part D benefit program which does not exclude off-label use. Recently announced proposed eligibility criteria by the CMS effectively exclude the coverage of off-label use of FDA-approved agents for cancer therapy and in other serious diseases. Today’s statement urges CMS officials to reverse this position and to make clear to the public and to medical providers that Medicare will reimburse for off-label use for medications and biological therapies in the demonstration project related to Section 641. And further, to make clear that any proposed or actual restriction on off-label use in the demonstration project is not a precedent for full enactment of the part D prescription drug benefit program. Pancreatic Cancer Facts: · Pancreatic cancer is the most virulent of the major cancers · Pancreatic cancer research is the least funded of the major cancers · Pancreatic cancer causes more than 1% of all death in the U.S. · Pancreatic cancer is the fourth most common cause of cancer mortality The Lorenzen Cancer Foundation is a 501(c)(3) non-profit organization dedicated to the fight against pancreatic cancer. LCF is oriented to increasing awareness and education about pancreatic cancer, helping physicians and patients create optimal treatment strategies, and fostering the development of a molecular or genetic marker to aid in diagnosis. For more information visit www.pancreatica.org Media Contact: Aaron Stoertz Media Relations Lorenzen Cancer Foundation (831) 658-0600 Company Contact: Ellen Pansky, esq. Director of Public Policy Lorenzen Cancer Foundation (831) 658-0600 About the author: . Check below for additional Medicare Prescription Benefit Links and Information |
Homepage Sitemap D Medicare Part plan prescription Aarp Medicare Prescription plan Drug Finder Medicare plan prescription Aarp Drug Medicare plan prescription Medicare Prescription Coverage Medicare Prescription Drug benefit
Add your link Additional Medicare Prescription Benefit Resources | ||
Prescription| Prescription Resources | Prescription Marketing |
|||
